Navigation Links
Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014
Date:7/22/2014

PORTLAND, Ore., July 22, 2014 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"), an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that it will report second quarter 2014 financial results before the open of U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler will host a conference call at 11 a.m. EDT, July 25, 2014.

The conference call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Second Quarter 2014 Financial Results Call, conference ID#: 78080334." The conference call will be archived on Semler's website at semlerscientific.com.

About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company.  Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler's first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec® received FDA 510(k) clearance in February 2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially leasing FloChec® in January 2011. Semler closed the initial public offering of its common stock on February 26, 2014 and its common stock is now listed on the NASDAQ Capital Market under the ticker symbol "SMLR." Additional information about Semler can be found at www.semlerscientific.com.

CONTACT:

Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650


'/>"/>
SOURCE Semler Scientific, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
11. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... , ... Avomeen & MichBio will be hosting a BioMixer next week Thursday, ... Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers are a casual, members-only ... with peers, make new connections and talk bio biz. , Cost:, ...
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... the "Synthetic Biology: Global Markets" report to ... ... synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis ... DNA synthesis and assembly, genome editing, bioinformatics and specialty ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
Breaking Biology Technology:
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... (ctDNA) technologies, today announced that it has signed agreements ... and the Middle East ... milestone marks the first wave of international distribution agreements ... and blood samples. The initial partners will ...
Breaking Biology News(10 mins):